TheraCryf | Ox-1 10kg toxicology study quantity achieved
TheraCryf has announced the successful manufacture of the 10kg quantity of its Ox-1 compound, sufficient to complete the critical 28-day regulatory toxicology studies in animals. These studies are expected to commence in 1Q26/2Q26 following the completion of dosing studies which are currently underway to identify the Maximum Tolerated Dose and Dose Range Finding Studies of the compound. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in humans by the end of 2026, a key value inflection point for which the company is fully funded. TheraCryf's valuation remains nugatory in relation to pharma deals for Central Nervous System compounds which typically attract upfront payments c5x TheraCryf's current market capitalisation for pre-clinical assets rising to c9x at clinical readiness.Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.